A Phase 3 interventional study of Secukinumab and Ustekinumab in Psoriatic Arthritis, sponsored by Novartis Pharmaceuticals. Completed at 28 sites in Germany. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-10-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing secukinumab in Arthritis, Psoriatic — 2 open to participants now, 2 under way, 1 of them phase 3. secukinumab · Arthritis, Psoriatic.
Among the 26 studies testing secukinumab in Arthritis, Psoriatic, this one is the 16th largest by enrollment, is one of 4 that started in 2020, is one of 16 in phase 3, and was the 22nd registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →2 of the 26 studies testing secukinumab in Arthritis, Psoriatic are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University of Erlangen-Nürnberg Medical School · Sites in Germany
Ages 18–75
By country, each count listing its studies:
secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 119 is below the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 231 across the 26 interventional studies. Of the 22 that completed or were terminated, 17 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 26 have an industry lead sponsor. The 8 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
31 studies in Arthritis, Psoriatic by Novartis: 3 open now, 3 under way, none of them phase 3. Of 28 finished, 19 (68%) have results posted.
Among the 31 studies in Arthritis, Psoriatic by Novartis, this one is the 17th largest by enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2020, is one of 14 in phase 3, and was the 19th registered.
Novartis’s Arthritis, Psoriatic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing secukinumab in Arthritis, Psoriatic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 31 in Arthritis, Psoriatic:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the safety and efficacy of secukinumab and ustekinumab in patients with active psoriatic arthritis who showed failure to previous TNFα-inhibitor treatment
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AIN457
Biological: Secukinumab · Biological: Ustekinumab
Biological: Secukinumab · Biological: Ustekinumab
Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
Also known as: AIN457
Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
Proportion of Patients With Health Assessment Questionnaire - Disability Index (HAQ-DI) Response at Week 28
The disability assessment component of the HAQ evaluated a subject's level of functional ability through 20 questions grouped into 8 categories: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item began with the prompt "Over the past week, are you able to…" and is scored on a 4-point scale: 0 (no difficulty), 1 (some difficulty), 2 (much difficulty), and 3 (unable to do). The overall score was calculated by averaging the scores across all answered domains, resulting in a total score ranging from 0 (no disability) to 3 (severe disability). A HAQ-DI response was defined as an improvement of ≥0.35 points from baseline at Week 28. Missing values were imputed as non-responders
Time frame: Baseline, Week 28
Number of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 28
The Psoriasis Area and Severity Index (PASI) was a composite measure that evaluates the average severity of erythema, induration, and desquamation of psoriatic lesions-each graded on a scale from 0 (none) to 4 (severe)-across four body regions: head, upper limbs, trunk (including groin), and lower limbs (to the top of the buttocks). These scores were weighted by the area of skin involvement in each region to generate a total PASI score ranging from 0 to 72, with higher scores indicating more severe disease activity. The number of participants who achieved at least a 90% reduction in PASI score from baseline at Week 28 was assessed. Missing values were imputed as non-responders.
Time frame: Baseline, Week 28
Change From Baseline in Patient's Assessment of Pain on VAS at Week 28
The patient's level of pain was evaluated using a horizontal Visual Analogue Scale (VAS), on which individuals marked their pain intensity with a vertical tick. The scale ranged from 0 mm (indicating "no pain") to 100 mm (indicating "unbearable pain"). The change in the patient's pain assessment on the VAS from baseline to Week 28 was analyzed. A negative change from baseline indicated improvement.
Time frame: Baseline, Week 28
Change From Baseline in Tender Joint Count (TJC) 68 at Week 28
Tender joint count (TJC) 68 was a method of assessing joint inflammation. Number of tender joints was determined by examining 68 joints and identifying the joints that were painful under pressure or to passive motion. The 68 joints assessed for tenderness included the 2 temporomandibular, 2 sternoclavicular, 2 acromioclavicular joints, 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal, 10 proximal interphalangeal, 8 distal interphalangeal joints of the hands, 2 hips, 2 knees, 2 talo¬tibial, 2 mid-tarsal, 10 metatarsophalangeal, and 10 proximal interphalangeal joints of the feet. The change from baseline in TJC68 at Week 28 was assessed. A negative change from baseline indicated improvement.
Time frame: Baseline, Week 28
Change From Baseline in Swollen Joint Count (SJC) 66 at Week 28
Swollen Joint Count (SJC) 66 was a method of assessing joint inflammation. The number of swollen joints was determined by examining 66 joints and identifying those with visible or palpable swelling suggestive of synovitis. The 66 joints assessed for swelling included the 2 sternoclavicular, 2 acromioclavicular joints, 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal, 10 proximal interphalangeal, 8 distal interphalangeal joints of the hands, 2 knees, 2 talotibial, 2 mid-tarsal, 10 metatarsophalangeal, and 10 proximal interphalangeal joints of the feet. The change from baseline in SJC66 at Week 28 was assessed. A negative change from baseline indicated improvement.
Time frame: Baseline, Week 28
Number of Patients Achieving PASI 100 at Week 28
The PASI was a composite measure that evaluates the average severity of erythema, induration, and desquamation of psoriatic lesions-each graded on a scale from 0 (none) to 4 (severe)-across four body regions: head, upper limbs, trunk (including groin), and lower limbs (to the top of the buttocks). These scores were weighted by the area of skin involvement in each region to generate a total PASI score ranging from 0 to 72, with higher scores indicating more severe disease activity. The number of participants who achieved 100% reduction in PASI score from baseline at Week 28 was assessed. Missing values were imputed as non-responders.
Time frame: Bseline, Week 28
Number of Patients Achieving PASI 75 at Week 28
The Psoriasis Area and Severity Index (PASI) was a composite measure that evaluates the average severity of erythema, induration, and desquamation of psoriatic lesions-each graded on a scale from 0 (none) to 4 (severe)-across four body regions: head, upper limbs, trunk (including groin), and lower limbs (to the top of the buttocks). These scores were weighted by the area of skin involvement in each region to generate a total PASI score ranging from 0 to 72, with higher scores indicating more severe disease activity. The number of participants who achieved at least a 75% reduction in PASI score from baseline at Week 28 was assessed. Missing values were imputed as non-responders.
Time frame: Baseline, Week 28
Change From Baseline in Patient's Global Assessment of Disease Activity on VAS
The patient's global assessment of disease activity was performed using a 100 mm (VAS) ranging from 0 (='very good') to 100 (='very poor') after the question 'Considering all the ways Psoriatic Arthritis affects you, please indicate with a vertical mark through the horizontal line how well you are today'. The change in the patient's global assessment on the VAS from baseline to Week 28 was analyzed. A negative change from baseline indicated improvement.
Time frame: Baseline, Week 28
Change From Baseline in Patient's Global Assessment of Psoriasis and Arthritis Disease Activity on VAS
The patient's assessment of psoriasis and arthritis was performed using a 100 mm VAS ranging from 0 (='Excellent') to 100 (='Poor') after the question 'Considering all the ways PSORIASIS and ARTHRITIS affects you, please indicate with a vertical mark through the horizontal line how well you are doing over the past week' The change in the patient's global assessment of psoriasis and arthritis disease activity on the VAS from baseline to Week 28 was analyzed. A negative change from baseline indicated improvement.
Time frame: Baseline, Week 28
Number of Patients Achieving Minimal Disease Activity (MDA) at Week 28
MDA was a composite endpoint used to assess low disease activity in patients with psoriatic arthritis and psoriasis. A patient was considered to have achieved MDA if they met at least 5 of the following 7 criteria: * TJC (0-68)≤1 * SJC (0-66 joints)≤1 * PASI ≤1 \[the total score ranged from 0 (no disease) to 72 (maximal disease)\] or body surface area≤3% * Patient's pain VAS ≤ 15 mm on a 100 mm scale, where 0 ="no pain" and 100= "pain as severe as can be imagined" * Patient's global assessment of disease activity (PtGA) ≤ 20 mm on a 100 mm scale, where 0 represented the lowest level of disease activity and 100 the highest * HAQ-DI ≤ 0.5, where 0 represented no difficulty and 3 represented inability to perform activities * Enthesitis count ≤ 1, based on the Leeds Enthesitis Index, where 0 indicated no tenderness and 6 indicated tenderness at all assessed tendon insertions The number of participants achieving MDA at Week 28 was assessed. Missing values were imputed as non-responders.
Time frame: Week 28
Change From Baseline in the Leeds Enthesitis Index (LEI)
The LEI was a validated enthesitis index that used six sites to evaluate enthesitis: the left and right lateral epicondyles of the humerus, the left and right proximal Achilles tendon insertions, and the left and right medial femoral condyles.Each site was scored as 0 (non-tender) or 1 (tender), resulting in a total score ranging from 0 to 6. A higher score reflected a greater burden of enthesitis. The change in the LEI score from baseline to Week 28 was analyzed. A negative change from baseline indicated an improvement in enthesitis severity
Time frame: Baseline, Week 28
Change From Baseline in the Leeds Dactylitis Index (LDI)
The LDI was used to quantitatively assess dactylitis by measuring the circumference of affected digits and their corresponding control digits, along with the tenderness of each affected digit. Digits were classified as dactylitic if there was a ≥10% difference in circumference compared to the contralateral digit. When both digits were affected or a contralateral control was unavailable, a standardized reference range was applied. For each dactylitic digit, the ratio of the affected to control circumference was multiplied by a binary tenderness score (1 = tender, 0 = non-tender). The resulting values were summed across all affected digits to calculate the total LDI score. Scores ranged from 0 to 20, with higher scores indicating more severe or widespread dactylitis. The change in the LDI score from baseline to Week 28 was analyzed. A negative change from baseline indicated an improvement in dactylitis severity.
Time frame: Baseline, Week 28
Change From Baseline in Psoriatic Arthritis Quality of Life (PsAQoL)
The PsAQoL questionnaire was used to assess the impact of psoriatic arthritis on patients' quality of life. The PsAQoL is a validated, disease-specific, self-administered instrument consisting of 20 items with binary response options ("true" or "not true"). Items covered physical, emotional, and social domains, including fatigue, independence, and interpersonal relationships. The total score ranged from 0 to 20, with higher scores indicating greater impairment in quality of life. The change in the PsAQoL score from baseline to Week 28 was analyzed. A negative change from baseline indicated an improvement in health-related quality of life.
Time frame: Baseline, Week 28
Percentage of Participants Achieving a Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Response at Week 28
The FACIT-Fatigue Scale was used to assess fatigue and its impact on daily functioning over the previous 7 days. The instrument consisted of 13 self-administered items, each scored on a 5-point Likert scale ranging from 0 ("Not at all") to 4 ("Very much"). The total score ranged from 0 to 52, with higher scores indicating less fatigue and better functioning. Response was achieved if the score had improved by at least 4 points from baseline. Missing values were imputed as non-responders
Time frame: Baseline, Week 28
Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Response at Week 28
The DLQI was used to evaluate the impact of dermatological conditions on patients' quality of life over the previous 7 days. It consisted of 10 self-administered items covering symptoms, daily activities, leisure, work/school, personal relationships, and treatment burden. Each item was scored from 0 ("Not at all") to 3 ("Very much"), with a total score ranging from 0 to 30. Higher scores indicated greater impairment. Response was achieved if the absolute score was either 0 or 1. Missing values were imputed as non-responders.
Time frame: Week 28
Patients were randomized in 28 study sites across Germany
| Milestone | Secukinumab | Ustekinumab |
|---|---|---|
| Started | 56 | 63 |
| Completed | 56 | 53 |
| Not completed | 0 | 10 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 4 |
| Withdrew: Loss of efficacy | 0 | 1 |
| Withdrew: Non-compliance with study drug | 0 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Subject decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
The disability assessment component of the HAQ evaluated a subject's level of functional ability through 20 questions grouped into 8 categories: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item began with the prompt "Over the past week, are you able to…" and is scored on a 4-point scale: 0 (no difficulty), 1 (some difficulty), 2 (much difficulty), and 3 (unable to do). The overall score was calculated by averaging the scores across all answered domains, resulting in a total score ranging from 0 (no disability) to 3 (severe disability). A HAQ-DI response was defined as an improvement of ≥0.35 points from baseline at Week 28. Missing values were imputed as non-responders
| Participants | Secukinumab | Ustekinumab |
|---|---|---|
| Proportion of Patients With Health Assessment Questionnaire - Disability Index (HAQ-DI) Response at Week 28 | 32 | 17 |
The Psoriasis Area and Severity Index (PASI) was a composite measure that evaluates the average severity of erythema, induration, and desquamation of psoriatic lesions-each graded on a scale from 0 (none) to 4 (severe)-across four body regions: head, upper limbs, trunk (including groin), and lower limbs (to the top of the buttocks). These scores were weighted by the area of skin involvement in each region to generate a total PASI score ranging from 0 to 72, with higher scores indicating more severe disease activity. The number of participants who achieved at least a 90% reduction in PASI score from baseline at Week 28 was assessed. Missing values were imputed as non-responders.
| Participants | Secukinumab | Ustekinumab |
|---|---|---|
| Number of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 28 | 27 | 25 |
The patient's level of pain was evaluated using a horizontal Visual Analogue Scale (VAS), on which individuals marked their pain intensity with a vertical tick. The scale ranged from 0 mm (indicating "no pain") to 100 mm (indicating "unbearable pain"). The change in the patient's pain assessment on the VAS from baseline to Week 28 was analyzed. A negative change from baseline indicated improvement.
| Score on a Scale | Secukinumab | Ustekinumab |
|---|---|---|
| Change From Baseline in Patient's Assessment of Pain on VAS at Week 28 | -27.1 ± 25.8 | -16.4 ± 24.2 |
Tender joint count (TJC) 68 was a method of assessing joint inflammation. Number of tender joints was determined by examining 68 joints and identifying the joints that were painful under pressure or to passive motion. The 68 joints assessed for tenderness included the 2 temporomandibular, 2 sternoclavicular, 2 acromioclavicular joints, 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal, 10 proximal interphalangeal, 8 distal interphalangeal joints of the hands, 2 hips, 2 knees, 2 talo¬tibial, 2 mid-tarsal, 10 metatarsophalangeal, and 10 proximal interphalangeal joints of the feet. The change from baseline in TJC68 at Week 28 was assessed. A negative change from baseline indicated improvement.
| Score on a Scale | Secukinumab | Ustekinumab |
|---|---|---|
| Change From Baseline in Tender Joint Count (TJC) 68 at Week 28 | -9.6 ± 11.9 | -7.6 ± 10.7 |
Swollen Joint Count (SJC) 66 was a method of assessing joint inflammation. The number of swollen joints was determined by examining 66 joints and identifying those with visible or palpable swelling suggestive of synovitis. The 66 joints assessed for swelling included the 2 sternoclavicular, 2 acromioclavicular joints, 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal, 10 proximal interphalangeal, 8 distal interphalangeal joints of the hands, 2 knees, 2 talotibial, 2 mid-tarsal, 10 metatarsophalangeal, and 10 proximal interphalangeal joints of the feet. The change from baseline in SJC66 at Week 28 was assessed. A negative change from baseline indicated improvement.
| Score on a Scale | Secukinumab | Ustekinumab |
|---|---|---|
| Change From Baseline in Swollen Joint Count (SJC) 66 at Week 28 | -6.8 ± 6.3 | -5.3 ± 5.2 |
The PASI was a composite measure that evaluates the average severity of erythema, induration, and desquamation of psoriatic lesions-each graded on a scale from 0 (none) to 4 (severe)-across four body regions: head, upper limbs, trunk (including groin), and lower limbs (to the top of the buttocks). These scores were weighted by the area of skin involvement in each region to generate a total PASI score ranging from 0 to 72, with higher scores indicating more severe disease activity. The number of participants who achieved 100% reduction in PASI score from baseline at Week 28 was assessed. Missing values were imputed as non-responders.
| Participants | Secukinumab | Ustekinumab |
|---|---|---|
| Number of Patients Achieving PASI 100 at Week 28 | 21 | 17 |
The Psoriasis Area and Severity Index (PASI) was a composite measure that evaluates the average severity of erythema, induration, and desquamation of psoriatic lesions-each graded on a scale from 0 (none) to 4 (severe)-across four body regions: head, upper limbs, trunk (including groin), and lower limbs (to the top of the buttocks). These scores were weighted by the area of skin involvement in each region to generate a total PASI score ranging from 0 to 72, with higher scores indicating more severe disease activity. The number of participants who achieved at least a 75% reduction in PASI score from baseline at Week 28 was assessed. Missing values were imputed as non-responders.
| Participants | Secukinumab | Ustekinumab |
|---|---|---|
| Number of Patients Achieving PASI 75 at Week 28 | 34 | 29 |
The patient's global assessment of disease activity was performed using a 100 mm (VAS) ranging from 0 (='very good') to 100 (='very poor') after the question 'Considering all the ways Psoriatic Arthritis affects you, please indicate with a vertical mark through the horizontal line how well you are today'. The change in the patient's global assessment on the VAS from baseline to Week 28 was analyzed. A negative change from baseline indicated improvement.
| Score on a Scale | Secukinumab | Ustekinumab |
|---|---|---|
| Change From Baseline in Patient's Global Assessment of Disease Activity on VAS | -26.0 ± 21.8 | -15.5 ± 23.1 |
The patient's assessment of psoriasis and arthritis was performed using a 100 mm VAS ranging from 0 (='Excellent') to 100 (='Poor') after the question 'Considering all the ways PSORIASIS and ARTHRITIS affects you, please indicate with a vertical mark through the horizontal line how well you are doing over the past week' The change in the patient's global assessment of psoriasis and arthritis disease activity on the VAS from baseline to Week 28 was analyzed. A negative change from baseline indicated improvement.
| Score on a Scale | Secukinumab | Ustekinumab |
|---|---|---|
| Change From Baseline in Patient's Global Assessment of Psoriasis and Arthritis Disease Activity on VAS | -28.1 ± 23.6 | -16.2 ± 24.8 |
MDA was a composite endpoint used to assess low disease activity in patients with psoriatic arthritis and psoriasis. A patient was considered to have achieved MDA if they met at least 5 of the following 7 criteria: * TJC (0-68)≤1 * SJC (0-66 joints)≤1 * PASI ≤1 \[the total score ranged from 0 (no disease) to 72 (maximal disease)\] or body surface area≤3% * Patient's pain VAS ≤ 15 mm on a 100 mm scale, where 0 ="no pain" and 100= "pain as severe as can be imagined" * Patient's global assessment of disease activity (PtGA) ≤ 20 mm on a 100 mm scale, where 0 represented the lowest level of disease activity and 100 the highest * HAQ-DI ≤ 0.5, where 0 represented no difficulty and 3 represented inability to perform activities * Enthesitis count ≤ 1, based on the Leeds Enthesitis Index, where 0 indicated no tenderness and 6 indicated tenderness at all assessed tendon insertions The number of participants achieving MDA at Week 28 was assessed. Missing values were imputed as non-responders.
| Participants | Secukinumab | Ustekinumab |
|---|---|---|
| Number of Patients Achieving Minimal Disease Activity (MDA) at Week 28 | 20 | 14 |
The LEI was a validated enthesitis index that used six sites to evaluate enthesitis: the left and right lateral epicondyles of the humerus, the left and right proximal Achilles tendon insertions, and the left and right medial femoral condyles.Each site was scored as 0 (non-tender) or 1 (tender), resulting in a total score ranging from 0 to 6. A higher score reflected a greater burden of enthesitis. The change in the LEI score from baseline to Week 28 was analyzed. A negative change from baseline indicated an improvement in enthesitis severity
| Score on a Scale | Secukinumab | Ustekinumab |
|---|---|---|
| Change From Baseline in the Leeds Enthesitis Index (LEI) | -0.9 ± 1.8 | -0.5 ± 1.5 |
The LDI was used to quantitatively assess dactylitis by measuring the circumference of affected digits and their corresponding control digits, along with the tenderness of each affected digit. Digits were classified as dactylitic if there was a ≥10% difference in circumference compared to the contralateral digit. When both digits were affected or a contralateral control was unavailable, a standardized reference range was applied. For each dactylitic digit, the ratio of the affected to control circumference was multiplied by a binary tenderness score (1 = tender, 0 = non-tender). The resulting values were summed across all affected digits to calculate the total LDI score. Scores ranged from 0 to 20, with higher scores indicating more severe or widespread dactylitis. The change in the LDI score from baseline to Week 28 was analyzed. A negative change from baseline indicated an improvement in dactylitis severity.
| Score on a Scale | Secukinumab | Ustekinumab |
|---|---|---|
| Change From Baseline in the Leeds Dactylitis Index (LDI) | -9.7 ± 27.2 | -7.2 ± 25.9 |
The PsAQoL questionnaire was used to assess the impact of psoriatic arthritis on patients' quality of life. The PsAQoL is a validated, disease-specific, self-administered instrument consisting of 20 items with binary response options ("true" or "not true"). Items covered physical, emotional, and social domains, including fatigue, independence, and interpersonal relationships. The total score ranged from 0 to 20, with higher scores indicating greater impairment in quality of life. The change in the PsAQoL score from baseline to Week 28 was analyzed. A negative change from baseline indicated an improvement in health-related quality of life.
| Score on a Scale | Secukinumab | Ustekinumab |
|---|---|---|
| Change From Baseline in Psoriatic Arthritis Quality of Life (PsAQoL) | -2.5 ± 5.1 | -2.0 ± 5.4 |
The FACIT-Fatigue Scale was used to assess fatigue and its impact on daily functioning over the previous 7 days. The instrument consisted of 13 self-administered items, each scored on a 5-point Likert scale ranging from 0 ("Not at all") to 4 ("Very much"). The total score ranged from 0 to 52, with higher scores indicating less fatigue and better functioning. Response was achieved if the score had improved by at least 4 points from baseline. Missing values were imputed as non-responders
| Participants | Secukinumab | Ustekinumab |
|---|---|---|
| Percentage of Participants Achieving a Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Response at Week 28 | 40 | 32 |
The DLQI was used to evaluate the impact of dermatological conditions on patients' quality of life over the previous 7 days. It consisted of 10 self-administered items covering symptoms, daily activities, leisure, work/school, personal relationships, and treatment burden. Each item was scored from 0 ("Not at all") to 3 ("Very much"), with a total score ranging from 0 to 30. Higher scores indicated greater impairment. Response was achieved if the absolute score was either 0 or 1. Missing values were imputed as non-responders.
| Participants | Secukinumab | Ustekinumab |
|---|---|---|
| Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Response at Week 28 | 30 | 32 |
Collected over From start of treatment to end of study, assessed up to approximately 36 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Secukinumab- On-Treatment | 0/56 (0%) | 3/56 (5.4%) | 27/56 (48.2%) |
| Ustekinumab - On-Treatment | 0/63 (0%) | 1/63 (1.6%) | 31/63 (49.2%) |
| Secukinumab - Entire Study | 0/56 (0%) | 4/56 (7.1%) | 31/56 (55.4%) |
| Ustekinumab - Entire Study | 0/63 (0%) | 2/63 (3.2%) | 32/63 (50.8%) |
| Event | Secukinumab- On-Treatment | Ustekinumab - On-Treatment | Secukinumab - Entire Study | Ustekinumab - Entire Study |
|---|---|---|---|---|
| Oesophageal candidiasisInfections and infestations | 0/56 | 0/63 | 1/56 | 0/63 |
| PneumoniaInfections and infestations | 1/56 | 0/63 | 1/56 | 0/63 |
| Urinary tract infectionInfections and infestations | 1/56 | 0/63 | 1/56 | 0/63 |
| Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/56 | 0/63 | 1/56 | 0/63 |
| Vertebrobasilar strokeNervous system disorders | 0/56 | 0/63 | 0/56 | 1/63 |
| PsoriasisSkin and subcutaneous tissue disorders | 0/56 | 1/63 | 0/56 | 1/63 |
| Event | Secukinumab- On-Treatment | Ustekinumab - On-Treatment | Secukinumab - Entire Study | Ustekinumab - Entire Study |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 5/56 | 9/63 | 7/56 | 9/63 |
| COVID-19Infections and infestations | 6/56 | 7/63 | 6/56 | 8/63 |
| Urinary tract infectionInfections and infestations | 4/56 | 5/63 | 5/56 | 6/63 |
| Psoriatic arthropathyMusculoskeletal and connective tissue disorders | 2/56 | 4/63 | 3/56 | 6/63 |
| DiarrhoeaGastrointestinal disorders | 5/56 | 4/63 | 5/56 | 4/63 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/56 | 5/63 | 5/56 | 5/63 |
| PsoriasisSkin and subcutaneous tissue disorders | 3/56 | 1/63 | 5/56 | 1/63 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 0/56 | 4/63 | 0/56 | 4/63 |
| Respiratory tract infectionInfections and infestations | 3/56 | 1/63 | 3/56 | 1/63 |
| Back painMusculoskeletal and connective tissue disorders | 3/56 | 3/63 | 3/56 | 3/63 |
| Age, Continuous(Years) | Secukinumab | Ustekinumab | Total |
|---|---|---|---|
| Mean | 54.4 ± 8.8 | 52.7 ± 12.7 | 53.5 ± 11.0 |
| Sex: Female, Male(Participants) | Secukinumab | Ustekinumab | Total |
|---|---|---|---|
| Female | 39 | 41 | 80 |
| Male | 17 | 22 | 39 |
| Race/Ethnicity, Customized(Participants) | Secukinumab | Ustekinumab | Total |
|---|---|---|---|
| Caucasian | 55 | 62 | 117 |
| Black | 1 | 0 | 1 |
| Other | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Dec 2020 to primary completion in Oct 2024, 46 months.
Results were first posted in Oct 2025, 11 months after primary completion.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 46 months is above that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Secukinumab · Ustekinumab